Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
PLoS One ; 14(7): e0219446, 2019.
Article in English | MEDLINE | ID: mdl-31276570

ABSTRACT

Amplification of a CAG trinucleotide motif (CTG18.1) within the TCF4 gene has been strongly associated with Fuchs Endothelial Corneal Dystrophy (FECD). Nevertheless, a small minority of clinically unaffected elderly patients who have expanded CTG18.1 sequences have been identified. To test the hypothesis that the CAG expansions in these patients are protected from FECD because they have interruptions within the CAG repeats, we utilized a combination of an amplification-free, long-read sequencing method and a new target-enrichment sequence analysis tool developed by Pacific Biosciences to interrogate the sequence structure of expanded repeats. The sequencing was successful in identifying a previously described interruption within an unexpanded allele and provided sequence data on expanded alleles greater than 2000 bases in length. The data revealed considerable heterogeneity in the size distribution of expanded repeats within each patient. Detailed analysis of the long sequence reads did not reveal any instances of interruptions to the expanded CAG repeats, but did reveal novel variants within the AGG repeats that flank the CAG repeats in two of the five samples from clinically unaffected patients with expansions. This first examination of the sequence structure of CAG repeats in CTG18.1 suggests that factors other than interruptions to the repeat structure account for the absence of disease in some elderly patients with repeat expansions in the TCF4 gene.


Subject(s)
Fuchs' Endothelial Dystrophy/genetics , Gene Amplification , Genetic Predisposition to Disease , Transcription Factor 4/genetics , Trinucleotide Repeat Expansion , Alleles , Computational Biology/methods , Fuchs' Endothelial Dystrophy/diagnosis , Gene Editing , Genetic Association Studies , Genomics/methods , Genotype , Humans , Phenotype , RNA, Guide, Kinetoplastida , Trinucleotide Repeats
2.
Neurodegener Dis ; 18(5-6): 239-253, 2018.
Article in English | MEDLINE | ID: mdl-30336474

ABSTRACT

BACKGROUND: European studies identified the C9orf72 repeat expansion as the most frequent genetic alteration in patients with Huntington disease (HD)-like phenotypes but negative HD genetic testing. OBJECTIVE: To investigate C9orf72 repeat expansion frequency in individuals tested for HD in a North American tertiary referral laboratory. METHODS: Three hundred and seventy-three cases (115 positive and 258 negative for HD) were evaluated by genotyping PCR, with follow-up Southern blot and 5' repeat methylation status assessment by combined repeat-primed and methylation-specific PCR in a subset. RESULTS: Three cases (all HD-negative) tested positive: 2 had > 2,000 repeats and were methylated, 1 had 80-100 repeats and was unmethylated. Two cases (1 HD-positive and 1 HD-negative) had intermediate alleles (20-29 repeats) and were unmethylated. The remaining 368 cases were negative (< 20 repeats). C9orf72 repeat expansion was absent in patients with HD and was identified in a small subset (1.2%) of patients with negative HD genetic testing. CONCLUSION: These findings suggest that C9orf72 repeat expansion does not coexist with HTT repeat expansion and that C9orf72 repeat expansion testing is unnecessary for patients with HD. In addition, C9orf72 evaluation may be considered for individuals negative for HD genetic testing. Similar to in previous studies, methylation of C9orf72 repeat expansion was limited to large expansions.


Subject(s)
C9orf72 Protein/genetics , DNA Repeat Expansion/genetics , Huntington Disease/genetics , Mutation/genetics , Adult , Aged , Amyotrophic Lateral Sclerosis/genetics , Female , Genetic Testing/methods , Humans , Male , Middle Aged , Phenotype
3.
Am J Clin Pathol ; 148(4): 296-307, 2017 Oct 01.
Article in English | MEDLINE | ID: mdl-28967952

ABSTRACT

OBJECTIVES: To develop and evaluate a real-time methylation-specific polymerase chain reaction (RT-MSP) MGMT assay, with a particular focus on small biopsies and indeterminate testing results. METHODS: We assessed formalin-fixed paraffin-embedded glioblastoma or gliosarcoma specimens (n = 641). A test-validation group (n = 51) with previously obtained reference laboratory (RL) results was used to determine performance characteristics of the RT-MSP assay. An indeterminate (equivocal) category was established for cases that could not be clearly classified as positive or negative. RESULTS: Overall agreement of RT-MSP and RL results was 91% (41/45 nonindeterminate cases). Discordant cases were tested by pyrosequencing, and results were most concordant with RT-MSP. Among cases with limited amounts of tissue (n = 7), six yielded valid results by RT-MSP (all negative); the single invalid result consisted of a stereotactic biopsy specimen obtained 14 years prior. A subset of indeterminate cases obtained during clinical testing (n = 18/575 [3%]) was also evaluated by pyrosequencing and showed a heterogeneous pattern of methylation across the eight interrogated CpG sites. CONCLUSIONS: The RT-MSP assay that we developed in-house is a robust clinical detection method for the heterogeneous process of MGMT promoter methylation in glioblastoma.


Subject(s)
Brain Neoplasms/genetics , DNA Modification Methylases/genetics , DNA Repair Enzymes/genetics , Glioblastoma/genetics , Real-Time Polymerase Chain Reaction/methods , Tumor Suppressor Proteins/genetics , DNA Methylation/genetics , Humans , Promoter Regions, Genetic/genetics
4.
Invest Ophthalmol Vis Sci ; 58(1): 343-352, 2017 01 01.
Article in English | MEDLINE | ID: mdl-28118661

ABSTRACT

Purpose: To identify RNA missplicing events in human corneal endothelial tissue isolated from Fuchs' endothelial corneal dystrophy (FECD). Methods: Total RNA was isolated and sequenced from corneal endothelial tissue obtained during keratoplasty from 12 patients with FECD and 4 patients undergoing keratoplasty or enucleation for other indications. The length of the trinucleotide repeat (TNR) CTG in the transcription factor 4 (TCF4) gene was determined using leukocyte-derived DNA analyzed by a combination of Southern blotting and Genescan analysis. Commercial statistical software was used to quantify expression of alternatively spliced genes. Validation of selected alternative splicing events was performed by using RT-PCR. Gene sets identified were analyzed for overrepresentation using Web-based analysis system. Results: Corneal endothelial tissue from FECD patients containing a CTG TNR expansion sequence in the TCF4 gene revealed widespread changes in mRNA splicing, including a novel splicing event involving FGFR2. Differential splicing of NUMA1, PPFIBP1, MBNL1, and MBNL2 transcripts were identified in all FECD samples containing a TNR expansion. The differentially spliced genes were enriched for products that localize to the cell cortex and bind cytoskeletal and cell adhesion proteins. Conclusions: Corneal endothelium from FECD patients harbors a unique signature of mis-splicing events due to CTG TNR expansion in the TCF4 gene, consistent with the hypothesis that RNA toxicity contributes to the pathogenesis of FECD. Changes to the endothelial barrier function, a known event in the development of FECD, was identified as a key biological process influenced by the missplicing events.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics , Fuchs' Endothelial Dystrophy/genetics , Gene Expression Regulation , Genetic Predisposition to Disease , RNA Splicing/genetics , RNA, Messenger/genetics , Transcription Factors/genetics , Adult , Aged , Aged, 80 and over , Alleles , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism , Blotting, Southern , Endothelium, Corneal/metabolism , Endothelium, Corneal/pathology , Female , Fuchs' Endothelial Dystrophy/diagnosis , Fuchs' Endothelial Dystrophy/metabolism , Genotype , Humans , Male , Middle Aged , Polymerase Chain Reaction , Transcription Factor 4 , Transcription Factors/metabolism , Trinucleotide Repeat Expansion
5.
J Mol Diagn ; 17(6): 689-94, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26321041

ABSTRACT

Genetic α-1 antitrypsin (AAT) deficiency is characterized by low serum AAT levels and the identification of causal mutations or an abnormal protein. It needs to be distinguished from deficiency because of nongenetic causes, and diagnostic delay may contribute to worse patient outcome. Current routine clinical testing assesses for only the most common mutations. We wanted to determine the proportion of unexplained cases of AAT deficiency that harbor causal mutations not identified through current standard allele-specific genotyping and isoelectric focusing (IEF). All prospective cases from December 1, 2013, to October 1, 2014, with a low serum AAT level not explained by allele-specific genotyping and IEF were assessed through full-gene sequencing with a direct sequencing method for pathogenic mutations. We reviewed the results using American Council of Medical Genetics criteria. Of 3523 cases, 42 (1.2%) met study inclusion criteria. Pathogenic or likely pathogenic mutations not identified through clinical testing were detected through full-gene sequencing in 16 (38%) of the 42 cases. Rare mutations not detected with current allele-specific testing and IEF underlie a substantial proportion of genetic AAT deficiency. Full-gene sequencing, therefore, has the ability to improve accuracy in the diagnosis of AAT deficiency.


Subject(s)
Mutation/genetics , alpha 1-Antitrypsin/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Alleles , Child , Child, Preschool , DNA Mutational Analysis/methods , Delayed Diagnosis , Female , Genotype , Humans , Infant , Male , Middle Aged , Phenotype , Prospective Studies , Young Adult , alpha 1-Antitrypsin Deficiency/genetics
6.
Invest Ophthalmol Vis Sci ; 56(8): 4865-9, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26218914

ABSTRACT

PURPOSE: The purpose of this study was to evaluate the association between the intronic expansion of a trinucleotide repeat (TNR) in the TCF4 gene and Fuchs' endothelial corneal dystrophy (FECD) in a Japanese population. METHODS: Forty-seven Japanese FECD patients and 96 age-matched controls were recruited. FECD patients and controls were examined by slit-lamp and noncontact specular microscopy. The repeat length was determined by direct sequencing and short tandem repeat assay of PCR-amplified DNA and Southern blotting of unamplified DNA. RESULTS: A TNR expansion, defined as >50 CTG repeats in the TCF4 gene was identified in 12 of 47 FECD cases (26%) and 0 of 96 controls (0%; P < 0.001). Sensitivity and specificity in this study were 26% and 100%, respectively. The clinical characteristics of FECD patients with TNR expansion were not distinct from those without TNR expansion. CONCLUSIONS: These findings show for the first time in a Japanese population the association of the TNR expansion in TCF4 with FECD. In contrast to Caucasian cohorts in whom the TNR expansion is present in most patients with FECD, a CTG expansion is present in a minority of Japanese subjects, indicating other genetic variants as common causes of phenotypically identical disease in this population.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics , DNA/genetics , Fuchs' Endothelial Dystrophy/genetics , Genetic Predisposition to Disease , Transcription Factors/genetics , Trinucleotide Repeat Expansion , Aged , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism , Blotting, Southern , Female , Fuchs' Endothelial Dystrophy/metabolism , Genotype , Humans , Introns , Japan , Male , Microsatellite Repeats , Polymerase Chain Reaction , Retrospective Studies , Transcription Factor 4 , Transcription Factors/metabolism
7.
Am J Surg Pathol ; 39(10): 1370-6, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26099011

ABSTRACT

Mismatch-repair (MMR) immunohistochemistry is used to detect tumor MMR deficiency associated with high-level microsatellite instability (MSI). Rare tumors show heterogenous loss of mutS homolog 6 (MSH6) with immunohistochemistry, defined by areas of retained staining and separate areas of complete loss of staining. To investigate the clinical interpretation of this phenomenon, we identified 22 cases of heterogenous MSH6 loss interpreted at Mayo Clinic from January 2001 through December 2012 and reviewed histologic features, MSH6 and other MMR immunohistochemistry, and accompanying MSI testing results (n=20). Heterogenous MSH6 loss was seen in colorectal carcinoma (n=18), endometrial carcinoma (n=3), and sebaceous neoplasm (n=1). In the 18 colorectal carcinoma cases, it accompanied complete loss of mutL homolog 1 (MLH1) or PMS2, or both. Heterogenous MSH6 loss was characterized by MSI and MSH6 C8 tract instability in treatment-naive cases and showed mucinous or signet-ring zones in one quarter of cases. Two cases status post neoadjuvant chemoradiation showed heterogenous MSH6 loss but were microsatellite and C8 tract stable. C8 tracts were unstable in 2 of 4 MSH6-associated Lynch syndrome (LS) tumors, but all 4 showed complete MSH6 loss on immunohistochemistry. Further, 12 such MSH6-associated LS cases showed complete MSH6 loss. In conclusion, heterogenous MSH6 loss is uncommon, usually caused by instability in MSH6 exon 5 polycytosine tract, and not associated with germline MSH6 mutation. Although heterogenous MSH6 loss provides evidence against germline MSH6 mutation, patients whose tumors exhibit this immunolabeling pattern may have LS due to a defect in a different MMR gene.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , DNA-Binding Proteins/genetics , Endometrial Neoplasms/genetics , Microsatellite Instability , Adult , Aged , Aged, 80 and over , Carcinoma/chemistry , Carcinoma/pathology , Carcinoma/therapy , Case-Control Studies , Colorectal Neoplasms, Hereditary Nonpolyposis/chemistry , Colorectal Neoplasms, Hereditary Nonpolyposis/pathology , Colorectal Neoplasms, Hereditary Nonpolyposis/therapy , DNA Mutational Analysis , Endometrial Neoplasms/chemistry , Endometrial Neoplasms/pathology , Endometrial Neoplasms/therapy , Exons , Female , Genetic Predisposition to Disease , Heredity , Humans , Immunohistochemistry , Male , Middle Aged , Minnesota , Mutation , Phenotype , Predictive Value of Tests , Young Adult
8.
PLoS One ; 7(11): e49083, 2012.
Article in English | MEDLINE | ID: mdl-23185296

ABSTRACT

Fuchs endothelial corneal dystrophy (FECD) is a common, familial disease of the corneal endothelium and is the leading indication for corneal transplantation. Variation in the transcription factor 4 (TCF4) gene has been identified as a major contributor to the disease. We tested for an association between an intronic TGC trinucleotide repeat in TCF4 and FECD by determining repeat length in 66 affected participants with severe FECD and 63 participants with normal corneas in a 3-stage discovery/replication/validation study. PCR primers flanking the TGC repeat were used to amplify leukocyte-derived genomic DNA. Repeat length was determined by direct sequencing, short tandem repeat (STR) assay and Southern blotting. Genomic Southern blots were used to evaluate samples for which only a single allele was identified by STR analysis. Compiling data for 3 arms of the study, a TGC repeat length >50 was present in 79% of FECD cases and in 3% of normal controls cases (p<0.001). Among cases, 52 of 66 (79%) subjects had >50 TGC repeats, 13 (20%) had <40 repeats and 1 (2%) had an intermediate repeat length. In comparison, only 2 of 63 (3%) unaffected control subjects had >50 repeats, 60 (95%) had <40 repeats and 1 (2%) had an intermediate repeat length. The repeat length was greater than 1000 in 4 FECD cases. The sensitivity and specificity of >50 TGC repeats identifying FECD in this patient cohort was 79% and 96%, respectively Expanded TGC repeat was more specific for FECD cases than the previously identified, highly associated, single nucleotide polymorphism, rs613872 (specificity = 79%). The TGC trinucleotide repeat expansion in TCF4 is strongly associated with FECD, and a repeat length >50 is highly specific for the disease This association suggests that trinucleotide expansion may play a pathogenic role in the majority of FECD cases and is a predictor of disease risk.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics , Fuchs' Endothelial Dystrophy/genetics , Genetic Predisposition to Disease , Transcription Factors/genetics , Trinucleotide Repeat Expansion/genetics , Aged , Aged, 80 and over , Alleles , Base Sequence , Blotting, Southern , Case-Control Studies , Chromosomes, Human, Pair 18/genetics , Female , Genome, Human/genetics , Humans , Male , Microsatellite Repeats/genetics , Middle Aged , Molecular Sequence Data , Reproducibility of Results , Sequence Analysis, DNA , Transcription Factor 4
9.
Gastroenterology ; 142(2): 248-56; quiz e25-6, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22062357

ABSTRACT

BACKGROUND & AIMS: Technical advances have led to stool DNA (sDNA) tests that might accurately detect neoplasms on both sides of the colorectum. We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance. METHODS: We performed a blinded, multicenter, case-control study using archived stool samples collected in preservative buffer from 252 patients with colorectal cancer (CRC), 133 with adenomas ≥ 1 cm, and 293 individuals with normal colonoscopy results (controls); two-thirds were randomly assigned to a training set and one-third to a test set. The sDNA test detects 4 methylated genes, a mutant form of KRAS, and the α-actin gene (as a reference value) using quantitative, allele-specific, real-time target and signal amplification; it also quantifies hemoglobin. We used a logistical model to analyze data. RESULTS: The sDNA test identified 85% of patients with CRC and 54% of patients with adenomas ≥1 cm with 90% specificity. The test had a high rate of detection for all nonmetastatic stages of CRC (aggregate 87% detection rate for CRC stages I-III). Detection rates increased with adenoma size: 54% ≥ 1 cm, 63% >1 cm, 77% >2 cm, 86% >3 cm, and 92% >4 cm (P < .0001). Based on receiver operating characteristic analysis, the rate of CRC detection was slightly greater for the training than the test set (P = .04), whereas the rate of adenoma detection was comparable between sets. Sensitivities for detection of CRC and adenoma did not differ with lesion site. CONCLUSIONS: Early-stage CRC and large adenomas can be detected throughout the colorectum and with high levels of accuracy by the sDNA test. Neoplasm size, but not anatomical site, affected detection rates. Further studies are needed to validate the findings in a larger population and optimize the sDNA test.


Subject(s)
Adenoma/diagnosis , Biomarkers, Tumor/analysis , Colorectal Neoplasms/diagnosis , Genetic Markers , Genetic Testing/methods , Actins/genetics , Adenoma/genetics , Adult , Aged , Aged, 80 and over , Bone Morphogenetic Protein 3/genetics , Case-Control Studies , Colorectal Neoplasms/genetics , Feces , Female , Glycoproteins/genetics , Humans , Logistic Models , Male , Middle Aged , Muscle Proteins/genetics , Nerve Tissue Proteins/genetics , Nucleic Acid Amplification Techniques , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins p21(ras) , Sensitivity and Specificity , Single-Blind Method , Vimentin/genetics , ras Proteins/genetics
10.
Clin Chem ; 52(12): 2236-42, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17053153

ABSTRACT

BACKGROUND: Laboratory testing in suspected alpha-1-antitrypsin (A1AT) deficiency involves analysis of A1AT concentrations and identification of specific alleles by genotyping or phenotyping. The purpose of this study was to define and evaluate a strategy that provides reliable laboratory evaluation of A1AT deficiency. METHODS: Samples from 512 individuals referred for A1AT phenotype analysis were analyzed by quantification, phenotype, and genotype. A1AT concentrations were measured by nephelometry. Phenotype analysis was performed by isoelectric focusing electrophoresis. The genotype assay detected the S and Z deficiency alleles by a melting curve analysis. RESULTS: Of the 512 samples analyzed, 2% of the phenotype and genotype results were discordant. Among these 10 discordant results, 7 were attributed to phenotyping errors. On the basis of these data we formulated an algorithm, according to which we analyzed samples by genotyping and quantification assays, with a reflex to phenotyping when the genotype and quantification results were not concordant. Retrospective analyses demonstrated that 4% of samples submitted for genotype and quantitative analysis were reflexed to phenotyping. Of the reflexed samples, phenotyping confirmed the genotype result in 85% of cases. In the remaining 15%, phenotyping provided further information, including identifying rare deficiency alleles and suggesting the presence of a null allele, and allowed for a more definitive interpretation of the genotype result. CONCLUSIONS: The combination of genotyping and quantification, with a reflex to phenotyping, is the optimal strategy for the laboratory evaluation of A1AT deficiency.


Subject(s)
alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin/genetics , Algorithms , Early Diagnosis , Genotype , Humans , Nephelometry and Turbidimetry , Phenotype , Retrospective Studies
11.
Gastroenterology ; 129(3): 846-54, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16143124

ABSTRACT

BACKGROUND & AIMS: A significant proportion of Lynch syndrome cases are believed to be due to large genomic alterations in the mismatch repair genes hMLH1 and hMSH2. However, previous studies have not adequately identified the frequency and scope of such mutations, and routine clinical Lynch syndrome testing often does not include analysis for these mutations. Our aim was to characterize hMLH1 and hMSH2 genomic rearrangements in a large population of suspected Lynch syndrome patients. METHODS: A total of 365 samples from probands referred for genetic testing for Lynch syndrome were analyzed for the presence of large genomic alterations in hMLH1 or hMSH2 by using a combination of techniques. Samples with a deletion in exons 1-6 in hMSH2 were further characterized by polymerase chain reaction to establish the presence of the hMSH2 American founder deletion. RESULTS: An hMLH1 or hMSH2 mutation was identified in 153 cases, and, of these, 12 of 67 (17.9%) and 39 of 86 (45.3%) had a large genomic alteration in hMLH1 and hMSH2, respectively. Overall, 6 different hMLH1 and 12 different hMSH2 deletions/duplications, including 10 novel mutations, were identified. Analysis of the hMSH2 exon 1-6 deletion samples showed that 13 of 18 (72.2%) had the American founder deletion. CONCLUSIONS: These data show a high frequency and diverse spectrum of large genomic alterations in hMLH1 and hMSH2 in suspected Lynch syndrome patients. Thus, a comprehensive mutation identification strategy that includes the ability to detect large genomic rearrangements is imperative for the clinical genetic identification of Lynch syndrome patients and families.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , DNA-Binding Proteins/genetics , Neoplasm Proteins/genetics , Nuclear Proteins/genetics , Proto-Oncogene Proteins/genetics , Adaptor Proteins, Signal Transducing , Age of Onset , Carrier Proteins , Exons , Female , Gene Dosage , Humans , Male , Middle Aged , MutL Protein Homolog 1 , MutS Homolog 2 Protein , Nuclear Family , Promoter Regions, Genetic , Retrospective Studies , Sequence Deletion
12.
Clin Chem ; 50(9): 1544-52, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15217993

ABSTRACT

BACKGROUND: Transthyretin-associated hereditary amyloidosis (ATTR) is an inherited disease in which variants in the primary structure of transthyretin (TTR; prealbumin) lead to the extracellular polymerization of insoluble protein fibrils, causing organ failure and ultimately death when major organs are involved. We have developed an integrated approach to molecular diagnosis with initial analysis of intact plasma TTR by electrospray ionization mass spectrometry (MS) and referral of positive samples for DNA sequence analysis and real-time PCR to confirm the common Gly6Ser polymorphism. METHODS: Samples from 6 patients previously diagnosed with ATTR and from 25 controls with (n = 15) or without (n = 10) polyneuropathy were analyzed in a blinded fashion for the presence of variant TTR. TTR protein was extracted with an immunoaffinity resin from 20 microL of archived plasma samples. The purified TTR was reduced with tris(2-carboxyethyl)phosphine and analyzed by MS. The appearance of two peaks (or a single peak shifted in mass indicative of a homozygous variant), including the wild-type mass of 13,761 Da, was indicative of the presence of a variant, and the individual was referred for DNA sequence analysis. RESULTS: MS analysis of intact reduced TTR correctly identified each of six samples known to contain variant TTR. These results were corroborated by subsequent DNA sequence analysis. Additionally, all Gly6Ser polymorphisms were correctly called based on the +30 mass shift and an equal relative abundance of the +30 polymorphism relative to wild-type TTR. No false-positive results were seen. CONCLUSIONS: This referral method eliminates the necessity of sequencing most samples and allows screening for the familial forms of amyloidosis in a broad patient population in a timely fashion. This method correctly identified all previously known variants and also identified a novel variant, Val94Ala.


Subject(s)
Amyloidosis, Familial/diagnosis , Genomics/methods , Prealbumin/genetics , Proteomics/methods , Amyloidosis, Familial/genetics , DNA/chemistry , DNA/genetics , Gas Chromatography-Mass Spectrometry/instrumentation , Gas Chromatography-Mass Spectrometry/methods , Genotype , Humans , Polymerase Chain Reaction , Polymorphism, Genetic , Prealbumin/chemistry , Sequence Analysis, DNA , Spectrometry, Mass, Electrospray Ionization/instrumentation , Spectrometry, Mass, Electrospray Ionization/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...